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Abstract:  Sickle  cell  disease  (SCD)  and  ß
hemoglobinopathies caused, respectively, by the alteration of structural features or deficient 
production of the ß-chain of the Hb molecule. Other hemoglobinopathi
different mutations in the α- or ß
require  periodic  or  chronic  blood  transfusions.  Therefore,  ß
hemoglobinopathies are excellent candidates for genetic
disorders and, potentially, could be cured by introducing or correcting a single gene into the 
hematopoietic compartment or a single stem cell. Initial attempts at gene transfer of these 
hemoglobinopathies have proved u
vectors.  With  the  advent  of  lentiviral  vectors  many  of  the  initial  limitations  have  been 
overcame. New  approaches have also focused on targeting the specific  mutation in the ß
globin genes, correcting the DNA sequence or manipulating the fate of RNA translation and 
splicing to restore ß-globin chain synthesis. These techniques have the potential to correct the 
defect into hematopoietic stem cells or be utilized to modify stem cells generated from pat
affected  by  these  disorders.  This  review  discusses  gene  therapy  strategies  for  the 
hemoglobinopathies, including the use of lentiviral vectors, generation of induced pluripotent 
stem cells (iPS) cells, gene targeting, splice
ß-thalassemia,  sickle  cell  anemia  and  other 
hemoglobinopathies: The thalassemias
of disorders due to a large number of heterogeneous 
mutations causing abnormal globin gene expression 
resulting  in  the  total  absence  or  quantitative 
reduction of globin chain synthesis
the α- or ß-globin gene lead to α- and ß
respectively
1.  α-Thalassemia  is  usually  due  to 
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Sickle  cell  disease  (SCD)  and  ß-thalassemia  represent  the  most  common 
hemoglobinopathies caused, respectively, by the alteration of structural features or deficient 
chain of the Hb molecule. Other hemoglobinopathies are characterized by 
or ß-globin genes and are associated with anemia and might 
require  periodic  or  chronic  blood  transfusions.  Therefore,  ß-thalassemia,  SCD  and  other 
hemoglobinopathies are excellent candidates for genetic approaches since they are monogenic 
disorders and, potentially, could be cured by introducing or correcting a single gene into the 
hematopoietic compartment or a single stem cell. Initial attempts at gene transfer of these 
hemoglobinopathies have proved unsuccessful due to limitations of available gene transfer 
vectors.  With  the  advent  of  lentiviral  vectors  many  of  the  initial  limitations  have  been 
overcame. New  approaches have also focused on targeting the specific  mutation in the ß
ng the DNA sequence or manipulating the fate of RNA translation and 
globin chain synthesis. These techniques have the potential to correct the 
defect into hematopoietic stem cells or be utilized to modify stem cells generated from pat
affected  by  these  disorders.  This  review  discusses  gene  therapy  strategies  for  the 
hemoglobinopathies, including the use of lentiviral vectors, generation of induced pluripotent 
stem cells (iPS) cells, gene targeting, splice-switching and stop codon readthrough.
thalassemia,  sickle  cell  anemia  and  other 
The thalassemias are a group 
of disorders due to a large number of heterogeneous 
mutations causing abnormal globin gene expression 
resulting  in  the  total  absence  or  quantitative 
reduction of globin chain synthesis
1. Mutations in 
and ß-thalassemia, 
Thalassemia  is  usually  due  to 
deletions within the α-globin gene cluster, leading 
to loss of function of one or both α
each locus
2. However, non-
been  described,  although  they  are  much  less 
frequent
1. Depending on the number of genes that 
are  unable  to  synthesize  the  α
different clinical manifestations can be observed. If 
one or two α-globin genes are  mutated (in 
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globin gene cluster, leading 
r both α-globin genes in 
-deletion mutations have 
been  described,  although  they  are  much  less 
. Depending on the number of genes that 
ze  the  α-globin  protein, 
different clinical manifestations can be observed. If 
globin genes are  mutated (in  cis or Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
trans),  normally  no  or  minimal  hematological 
effects are seen, and individuals are normally silent 
thalassemia carriers or show α-thalassemia trait
1. If 
three out of four genes are mutated, the condition is 
called hemoglobin H (HbH) disease, resulting in a 
hemolytic  anemia  that  can  worsen  with  febrile 
illness or exposure to certain drugs, chemicals, or 
infectious  agents.  Hemoglobin  H  disease  is 
characterized  by  moderate  to  severe  anemia, 
hepatosplenomegaly,  and  jaundice.  Transfusion 
may  occasionally  be  required  and,  if  provided 
frequently, can lead to iron overload. If all four α-
globin genes are deleted, the resulting condition is 
called α-thalassemia major, which is so severe that 
death  occurs  in  utero.  Children  rescued  through 
intrauterine  transfusions  remain  dependent  on  red 
blood cell transfusions for survival
3.
The  thalassemias  are  characterized  by  their 
clinical  severity  and  genetic  mutations.  Patients 
with Cooley’s anemia, also known as ß-thalassemia 
major,  which  is  the  most  severe  form  of  this 
disease, require many blood  transfusions per year 
and  is  characterized  by  ineffective  erythropoiesis 
and  extra  medullary  hematopoiesis  (EMH)
1.  If 
untreated, ß-thalassemia  major  is fatal in  the first 
few  years  of  life
1.  In  ß-thalassemia  intermedia, 
where  a  greater  number  of  ß-globin  chains  are 
synthesized, the clinical picture is milder, and the 
patients  require  only  infrequent  or  no 
transfusions
4,1. In both thalassemias, with time the 
spleen is enlarged, the hemoglobin level decreases, 
and  progressive  iron  overload  occurs  from 
increased  GI  iron  absorption  in  addition  to 
transfusions
1.  The  vast  majority of  ß-thalassemias 
are caused by point mutations within the gene or its 
immediate  flanking  sequences  and  are  classified 
according to the mechanism by which they affect 
gene regulation: transcription, RNA processing and 
mRNA  translation
1.  These  mutations  are  also 
classified as ß0 and ß+ according to the quantity of
ß-globin chains synthesized. Mutations that lead to 
alternative  splicing  are  associated  with  reduced 
synthesis  of  normal  ß-globin  mRNA  and  protein 
and  are  defined  ß+.  In  contrast,  mutations  that 
completely impair ß-globin synthesis (for instance 
premature termination codons or PTCs) are defined 
ß0. Depending on the association of these different 
mutations, patients are classified into three principal 
groups  with none,  very  low  or  low  ß-globin 
production (ß0/0, 0/+, +/+ respectively). The levels 
of fetal hemoglobin (HbF) account for a large part 
of the clinical heterogeneity observed in patients 
with ß-thalassemia. Variation in HbF expression 
among individuals is an inheritable disease modifier 
and high HbF (composed from 2 α- and 2 γ-chains) 
levels  generally  correlate  with  reduced  morbidity 
and  mortality  in  this  disorder,  since  the  γ-globin 
chains combine with the excess α-chains. 
A  single  mutation  leads  to  SCD,  causing  an 
adenine (A) to thymidine (T) substitution in codon 
6 (GAG-GTG), which leads to insertion of valine in 
place of glutamic acid in the ß-globin chain. The 
resulting  Hb  (HbS)  has  the  unique  property  of 
polymerizing  when  deoxygenated
1.  When  the 
polymer becomes abundant, the red cells “sickle”, 
stiff rods form that stretch and distort the red cells. 
These  distorted  cells  can  obstruct  blood  flow 
through the small vessels, and the restricted oxygen 
delivery to the tissues damages cells, injures organs, 
and  produces  pain.  Similarly  to  SCD,  other 
hemoglobinopathies  can  be  triggered  by  the 
substitution of one amino acid (HbE
5,6,2), deletion of 
a  portion  of  the  amino  acid  sequence  (Hb  Gun 
Hill
7), abnormal hybridization between two chains 
(Hb Lepore
8,9), or abnormal elongation of the globin 
chain (Hb Constant Spring
10). These abnormal Hbs 
can  have  a  variety  of  pathophysiologically 
significant  effects,  including  ineffective 
erythropoiesis and anemia
1.
SCD  and  the  thalassemias are  quite  common 
among  Asian,  African,  African-American  and 
Mediterranean populations
1.  It has been estimated 
that approximately 7% of the world population are 
carriers  of  such  disorders,  and  that  300,000–
400,000  children  with  severe  forms  of  these 
diseases are born each year
117. 
Hematopoietic stem cell transplantation: Current 
disease  management  of  ß-thalassemia  consists  of 
prenatal  diagnosis,  transfusion  therapy,  or 
allogeneic  BMT
11-13. Only the  latter is  potentially 
curative
14. The  first  successful  BMT  of  ß-
thalassemia was reported in 1982
15. Consequently, 
several  centers  have  utilized  this  approach  as 
definitive  therapy
16-18.  The  most  extensive 
experience  in  treating  ß-thalassemia  patients  with 
BMT is that of Lucarelli and coworkers in Italy
18. 
Established protocols can lead to a high success of 
thalassemia-free  survival,  although  the  transplant-
related mortality is still significant and the chronic 
graft-versus-host  disease  is  still  a  potential  long-
term  complication  of  allogeneic  HSCs 
transplantation
17,19.  In  addition,  availability  of 
allogeneic  bone  marrow  is  limited  by  finding  an 
identical human leucocyte antigen (HLA) matched 
bone marrow donor. However, development of new 
techniques  to  improve  the  management  of  graft-
versus-host  disease,  to  perform  BMT  from Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
unrelated  donors  and  cord  blood  stem  cells  may 
expand  the  pool  of  potential  donors  in  the  near 
future
20.
In  addition,  patients  with  severe  ß-thalassemia 
and  SCD  might  benefit  from  new  genetic  and 
cellular  approaches.  From  this  prospective,  ß-
thalassemia  and  SCD  are  excellent  candidate 
diseases  for  genetically  based  therapies  in 
autologous  hematopoietic  stem  cells  (HSCs)
21-23. 
Alternatively,  somatic  cells  reprogrammed  to 
induced pluripotent stem cells might also provide a 
possible new approach to treat ß-thalassemia
24,25.
Gene transfer using oncoretroviral vectors: Gene 
addition  mediated  by  retroviral  vectors  is  an 
attractive  approach  for  monogenic  disorder, 
However, when applied to hemoglobinopathies, this 
strategy  raises  major  challenges  in  terms  of 
controlling transgene expression, which should be 
erythroid-speciﬁc,  elevated,  position  independent 
and sustained over time. In fact, many studies were 
performed  before  positive  preclinical  data  were 
generated.  The  first  attempts  were  done  using 
oncoviruses.  These  viruses  belong  to  the  large 
family of Retroviridae and are characterized by a 
genome that encodes the genes gag-pol and env
26. 
Onco-retroviral vectors, such as those derived from 
Moloney murine leukemia virus, efficiently transfer 
therapeutic  genes  into  murine hematopoietic  stem 
cells  (HSC)  without transferring any viral  gene
27. 
Recombinant  oncoretroviruses  were  the  first  viral 
vectors used to transfer the human ß-globin gene in 
mouse  HSCs
28,29.  These  experiments  resulted  in 
tissue-specific  but  low  and  variable  (position-
dependent)  human  ß-globin  expression  in  bone 
marrow  chimeras,  usually varying  between  0  and 
2%  of  endogenous  mouse  ß-globin  mRNA 
levels
29,30-33. Studies aimed at increasing expression 
levels of transferred ß-globin genes have focused on 
including locus  control region  (LCR) elements of 
the human ß-globin gene locus into oncoretroviral 
vectors.  The  LCR  contains  cis-acting  DNase  I 
hypersensitivity sites (HS) that are critical for high-
level,  long-term,  position-independent,  and 
erythroid-specific  expression
34,35.  These  HS 
elements  contain  several  DNA-binding  motifs  for 
transcriptional  and  chromatin  remodeling  factors 
that  facilitates  chromatin  opening.  Also,  thes 
genomic  regions  allow  for  binding  of  other 
regulatory  elements  required  for  high-level 
expression of the ß-globin gene
36. Incorporation of 
the  core  elements  of  HS2,  HS3,  and  HS4  of  the 
human  ß-globin  LCR  significantly  increased 
expression levels in murine erythroleukemia (MEL) 
cells but failed to abolish positional variability of 
expression
37,35. Additional efforts aimed to include 
larger elements resulted in the inability of the vector 
to incorporate large quantities of genetic material, 
as shown by the rearrangements of the transferred 
sequences
38-41.  Since  these  rearrangements 
frequently occur because of  activation of splicing 
sites  of  the  LCR  sequence  contained  in  the 
retroviral  RNA,  additional  attempts  were  done  to 
eliminate  these  sites.  However,  even  these  new 
vectors  failed  to  include  HS  elements  sufficient 
large to considerably increase expression of the ß-
globin gene
37,35.
Additional  erythroid-specific  transcriptional 
elements  were  investigated  within  oncoretroviral 
vectors, including the HS40 regulatory region from 
the  human  α-locus
42-44 and  alternative  promoters. 
The  promoter  of  ankyrin,  a  red  cell  membrane 
protein, has shown some promise in transgenic mice 
and in transduced MEL cells
45. In mice, the ankyrin 
promoter has been used to drive expression of the 
human γ-globin gene resulting, at double copy, in 
an  average  expression  of  8%  of  that  of  the 
endogenous  α-globin  genes
46.  To  overcome 
transcriptional silencing of the γ-globin promoter in 
hematopoietic chimeras, mutant γ-globin promoters 
from  patients  with  hereditary  persistence  of  fetal 
hemoglobin  (HPFH)  were  also  investigated
118,47. 
The Greek mutation at position −117 thus appeared 
to  substantially  increase  γ-globin expression  in 
MEL cells
47.  However, even these vectors failed to 
increase  the  level  of  the  ß-globin  gene  to 
therapeutic levels.
Although  oncoretrovirus  vectors  integrate  into 
the  genome,  many  integrants  undergo 
transcriptional  silencing,  posing  an  additional 
challenge to the success of gene therapy using these 
vectors.  Kalberer  and  co-workers  attempted  to 
avoid  gene  silencing  by  preselecting  ex  vivo 
retrovirally transduced hematopoietic stem cells on 
the  basis  of  expression  of  the  green  fluorescent 
protein  (GFP).  In  this  vector  the  GFP  gene  was 
driven  by  the  phosphoglycerate  kinase  promoter, 
while the human ß-globin gene by its own promoter 
and  small  elements  from  the  LCR
48.  Using  this 
approach,  in  vivo hematopoietic  stem  cell  gene 
silencing  and  age-dependent  extinction  of 
expression  were  avoided,  although  suboptimal 
expression levels and heterocellular position effects 
persisted.
Another  major  limitation is  that  oncoretroviral 
vectors need to infect cells before and close to their 
division,  otherwise the  viral  RNA cannot  migrate 
into the nucleus due to the presence of a nuclear Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
membrane
49.  Since  most hematopoietic  stem cells 
are in a quiescent state, they must be induced with 
cytokines  to  divide  in  order  to  achieve  higher 
transduction  efficiencies  and  overall  expression 
levels. Stimulation of quiescent hematopoietic stem 
cells,  however,  impairs  or  halts  their  long-term 
repopulating capacities
49. 
Gene  Transfer  Using  Lentiviral  Vectors: With 
the extensive research on human immunodeficiency 
virus-1,  it  has  been  realized  that  lentivirus, 
engineered  to  be  devoid  of  any  pathogenic 
elements,  can  become  efficient  gene  transfer 
vectors.  Lentiviruses  are  characterized  by  a 
complex  genome  that  encodes  a  number  of 
accessory proteins besides the canonical retroviral 
genes gag-pol and env. They share all the common 
characteristic  of  retroviral  replication  including 
receptor-mediated entry, capsid uncoating, reverse 
transcription of the viral RNA, and integration into 
the host cell genome
26. In addition, they are able to 
transduce  non-replicating  cells,  which  confers  to 
these viruses a special value for the development of 
clinically  functional  gene  vectors.  Moreover, 
compared to oncoretroviral vectors, the stabilization 
of the proviral mRNA genome by the interaction of 
the  accessory  protein  Rev  with  its  cognate  motif 
Rev-responsive  element  (RRE),  increases  their 
range of application, since larger genomic elements 
can be introduced in their genome with limited or 
no  sequence  rearrangement
50.  Therefore,  lentiviral 
vectors are thus likely to be selected as vectors of 
choice  for  the  stable  delivery  of  regulated 
transgenes in stem cell–based gene therapy. The use 
of lentiviral vectors has allowed the introduction of 
large  genomic  elements  from  the  ß-globin  locus, 
different  promoters,  enhancers,  and  chromatin 
structure  determinants  that  led  to  lineage-speciﬁc 
and elevated of ß-, γ- and  α-globin expression in 
vivo. This resulted, in the amelioration or correction 
of anemia and secondary organ damage in several 
murine models of hemoglobinopathies, making the 
recombinant lentiviruses the most effective vector 
system to date for gene therapy of these disorders. 
α-Thalassemia could potentially be a target for 
fetal gene therapy since fetuses with this disorder 
usually die between the third trimester of pregnancy 
and soon after birth. The potential use of lentiviral 
vectors  to  treat  α-thalassemia  was  investigated  a 
vector  containing  the  HS2,  3,  and  4  of  the  LCR 
from the human ß-globin locus, and the human α-
globin gene promoter directing the human α-globin 
gene.  Using  this  vector,  Han  and  colleagues 
performed  gene  delivery  in  utero  during 
midgestation targeting embryos affected by a lethal 
form  of  α-thalassemia.  They  showed  that  in 
newborn mice, the human α-globin gene expression 
was  detected  in  the  liver,  spleen,  and  peripheral 
blood
51. The human α-globin gene expression was 
at the peak at 3–4 months, when it reached 20% in 
some recipients. However, the expression declined 
at 7 months. Colony-forming assays in these mice 
showed  low  levels  of  transduction  and  lack  of 
human α-globin transcript. Thus, lentiviral vectors 
can be an effective vehicle for delivering the human 
α-globin gene into erythroid cells in utero, but, in 
the  mouse  model,  delivery  at  late  midgestation 
could  not  transduce  hematopoietic  stem  cells 
adequately to sustain gene expression.
Treatment  of  ß-thalassemia,  SCD  and  other 
disorders through lentiviral mediated gene transfer 
is  studied in  murine and primate models
52-60. The 
original  studies  in  mice  showed  that  lentiviral 
mediated human ß-globin gene transfer can rescue 
mice affected  by ß-thalassemia  intermedia  and ß-
thalassemia major
61,62,59. The mouse ß-globin cluster 
has  two  adult  ß-globin  genes,  ß
minor- and  ß
major-
globin.  Thalassemic  mice  were  generated  with 
deletion of both the ß
minor- and ß
major-globin on one 
allele, designated th3/+ mice (63; 64). Also adult 
th3/+  mice  have  a  degree  of  disease  severity 
(hepatosplenomegaly, anemia, aberrant erythrocyte 
morphology) comparable to that of patients affected 
by ß-TI. May and colleagues tested two lentiviral 
vectors termed RNS1 (carrying minimal core LCR 
elements)  and  TNS9  (with  large  LCR  fragments 
encompassing HS2, HS3 and HS4; approximately 
3.2 kb in size) on th3/+ mice. Compared to RNS1, 
mice recipient of the larger TNS9 vector maintained 
higher human ß-globin  transcript levels over time 
showing  amelioration  of  red  cell  pathology
(anisocytosis  and  poikilocytosis)  and  significantly 
increased hemoglobin levels (from 8-9 g/dL to 11-
13  g/dL).  The  massive  splenomegaly  found  in 
chimeras engrafted with control th3/+ bone marrow 
was not observed in TNS9-treated animals
61. This 
correction was sustained in secondary mice
62.
Mice  completely  lacking  adult  ß-globin  genes 
(th3/th3)  die  late  in  gestation,  limiting  their 
utilization  as  a  model  for  Cooley's  anemia
64.  For 
this  reason,  adult  animals  affected  by  Cooley’s 
anemia  were  generated  by  transplantation  of 
hematopoietic  fetal  liver  cells  harvested  from 
th3/th3 embryos  at  E14.5  into  lethally  irradiated 
syngeneic  adult  recipients
59.  Hematological 
analyses of engrafted mice performed 6 to 8 weeks 
post-transplant revealed severe anemia due not  to 
pancytopenia but rather to low red blood cell and Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
reticulocyte  counts  together  with  massive 
splenomegaly  and  extensive  EMH
62,59.  These 
animals could be rescued using TNS9 or by blood 
transfusions,  supporting  the  notion  that  their 
phenotype  is  due  specifically  to  erythroid 
impairment
65,59. 
Pawliuk and colleagues investigated the efficacy 
of  a  lentiviral  vector  harboring  the  ß-globin 
promoter, LCR elements and a mutated human ß-
globin  gene  with  enhanced  anti-sickling  activity 
(ß87) in two different transgenic mouse models for 
SCD: SAD and BERK
66,67. Mice transplanted with 
BERK and SAD bone marrow cells transduced with 
this  modified  ß-globin  gene  exhibited  corrected 
reticulocyte counts and amelioration of Hemoglobin 
concentration,  anisocytosis,  and  poikilocytosis. 
Moreover,  the  proportion  of  irreversibly  sickled 
cells,  SCD-associated  splenomegaly,  and 
characteristic urine concentration defect in SAD and 
BERK mice were vastly improved or corrected by 
ß87.  Using  a  similar  vector,  Levasseur  and 
colleagues  obtained  equivalent  results.  They 
transduced  Sca1+c-Kit+Lin−  cells  rather  than 
unselected bone marrow cells and achieved durable 
therapeutic  results  (5–7  months)  following 
transplantation  of  100  cells  in  lethally  irradiated 
C57BL/6 mice
113,114.
Samakoglu and coworkers applied the principle 
of RNA interference (RNAi) to down-regulate the 
ß-globin  mRNA  in  CD34(+)  cells  from  patients 
affected by SCD
116. They utilized a lentiviral vector 
harboring  a  promoterless  small-hairpin  RNA 
(shRNA)  within  the  intron  of  a  recombinant  γ-
globin  gene. Expression of  both  γ-globin and  the 
lariat-embedded  small  interfering  RNA  (siRNA) 
was  induced  upon  erythroid  differentiation, 
specifically  downregulating  the  targeted  gene  in 
tissue and differentiation stage-specific fashion. The 
position of the shRNA within the intron was critical 
to concurrently achieve high transgene expression, 
effective siRNA generation and minimal interferon 
induction. 
Miccio and colleagues also utilized an erythroid-
specific lentiviral vector driving the expression of 
the  human  ß-globin  gene  from  a  minimal 
promoter/enhancer  element  containing  two 
hypersensitive sites from the ß-globin locus control 
region in mouse models of ß-thalassemia (68). They 
showed  that  genetically  corrected  erythroblasts 
underwent  in  vivo selection.  The  selected 
erythroblast that derived from progenitors harboring 
proviral integrations in genome sites and were more 
favorable to high levels of vector expression. These 
data  suggested  that  a  regimen  of  partially
myeloablative transplantation might be sufficient to 
achieve a  chimerism that  would  therapeutic in  ß-
thalassemic patients. 
While  correction  of  murine  models  of  ß-
thalassemia  has  been  achieved through  lentiviral-
mediated  high  levels  of  globin  gene  transfer  into
mouse HSCs, transduction of human HSCs is less 
robust and may be inadequate to achievetherapeutic 
levels of genetically modified erythroid cells. Zhao 
and coworkers therefore developed a double gene 
lentiviral  vector  encoding both  human  γ-globin 
under  the  transcriptional  control  of  erythroid
regulatory  elements  and  methylguanine 
methyltransferase (MGMT),driven by a constitutive 
cellular  promoter
60.  MGMT  is  an  alkyltransferase
that  normally  functions  to  repair  cellular  DNA 
damage  at  the O
6 position  of  guanine
69,70.  The 
cytotoxic  effects  of  alkylating agents,  such as 
temozolomide and 1,3-bis-chloroethyl-1-nitrosourea
(BCNU),  can  be  prevented  if  there  is  adequate 
expression ofMGMT, which removes the O
6 adduct 
from the modified DNA. Variant MGMT proteins 
with specific amino acid changes retain significant 
activity  while  possessing  the useful  property  of 
resistance  to  inactivation  by  O
6-benzylguanine
(BG)
71. BG can be used to inactivate endogenous 
MGMT  to  enhance the  specificity  of  alkylator-
mediated  cell  death  to  cells  not expressing  the 
variant form. Therefore, expression of these variant 
forms  of  MGMT  provides  cellular  resistance  to 
alkylator drugs, which can be administered to kill 
residual  untransduced  HSCs,  whereas transduced 
cells  are  protected.  To  test  this  hypothesis,  mice 
transplanted  with  ß-thalassemic HSCs  cells 
transduced with a lentiviral γ-globin/MGMT vector 
were treated with BCNU
60. This led to significant
increas  in  the  number  of  γ-globin–expressing  red 
cells,the amount of fetal hemoglobin and resolution 
of anemia. One important advantage of using the γ-
globin gene, normally expressed exclusively during 
fetal  life,  is  that  high  level  γ-globin  expression 
would be therapeutic not only for ß-thalassemia, but 
also  SCD.  Interestingly,  selection  of  transduced 
HSCs  was  also  obtained  when cells  were  drug-
treated  before  transplantation.  These  data  suggest 
that coexpression of MGMT allowed autologous, γ-
globin vector-transduced ß-thalassemic HSCs to be 
enriched to therapeutic levels through either pre or
post-transplantation selection. 
Imren and colleagues engrafted immunodeficient 
mice with human cord blood cells infected with a 
lentiviral vector encoding an anti-sickling ß-globin 
transgene
35,72.  After  6-months,  half  of  the  human 
erythroid  and  myeloid  progenitors  regenerated  in Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
the  mice  containing  the  transgene,  and  erythroid 
cells derived in vitro from these cells produced high 
levels  of  the  ß-globin  protein.  In  addition,  these 
authors investigated the integrated proviral copies 
showing  that  86%  of  the  proviral  inserts  had 
occurred  within  genes,  including  several  genes 
implicated  in  human  leukemia.  These  findings 
indicate  effective  transduction  of  very  primitive 
human  cord  blood  cells  achieving  robust  and 
erythroid-specific  production  of  therapeutically 
relevant levels of ß-globin protein. The frequency 
of proviral integration within genes observed in this 
study and the data from Miccio and coworkers that 
indicate  that  selected  erythroblasts  were  derived 
from  progenitors  harboring  proviral  integrations 
more favorable to high levels of vector expression, 
indicate that regulated hematopoiesis might require 
additional safety modifications to prevent potential 
genotoxic effects
35,72,68. This risk is inherent to the 
integration of foreign genetic material and the risk 
of insertional oncogenesis has been established both 
in mice and humans
73-78. 
In light of these results, genetic elements with 
enhancer-blocking  properties,  such  as  insulators, 
could increase the safety of the clinical trails. These 
elements  have  been  investigated  to  shelter  the 
vector  from  the  repressive  influence  of  flanking 
chromatin  by  blocking  interactions  between 
regulatory  elements  within  the  vector  and 
chromosomal elements at the site of integration
79-81. 
This property of insulators can also be harnessed to 
diminish  the  risk  that  the  vector  will  activate  a 
neighboring  oncogene
82,83.  The  initial  studies 
indicated  that  inclusion  of  the  cHS4  insulator 
element  into  the  3′  LTR  of  recombinant  murine 
leukemia  virus  increases  the  probability  that 
randomly  integrated  proviruses  will  express  the 
transgene
46,84-86. Puthenveetil and coworkers tested 
a  lentiviral  vector  carrying  the  human  ß-globin 
expression cassette flanked by a chromatin insulator 
in  transfusion-dependent  human  ß-thalassemia 
major cells
87. Using this vector, they demonstrated 
normal expression of human ß-globin in erythroid 
cells  produced  in  vitro.  They  also  observed 
restoration of effective erythropoiesis and reversal 
of  the  abnormally  elevated  apoptosis  that 
characterizes  ß-thalassemia.  The  gene-corrected 
human  ß-thalassemia  progenitor  cells  were  also 
transplanted  into  immune-deficient  mice,  where 
they  underwent  normal  erythroid  differentiation, 
expressed  normal  levels  of  human  ß-globin,  and 
displayed  normal  effective  erythropoiesis  3  to  4 
months after xenotransplantation. Based on all these 
preclinical  studies  on  mouse  models  of  ß-
thalassemia  and  SCD,  clinical  trials  have  been 
proposed or are underway
53. Figure 1A depicts this 
approach.
Alternatively,  the  homologous  recom-bination
pathway  can  be  harnessed  to  avoid  random 
integration. Zinc-finger nucleases (ZFNs) can been 
used  to  enhance  the  frequency  of  gene 
correction
88,89. However, achieving the full potential 
of  ZFNs  for  genome  engineering  in  human  cells 
requires their efficient delivery to the relevant cell 
types.  Lombardo  and  colleagues  exploited  the 
infectivity  of  integrase-defective  lentiviral  vectors 
(IDLV) to express ZFNs and provide the template 
DNA for gene correction in different cell types
90. 
IDLV-mediated delivery supported high rates (13–
39%)  of  editing  at  the  IL-2  receptor  common  γ-
chain  gene (IL2RG) across different cell  types as 
well as human embryonic stem cells (5%), allowing 
selection-free isolation of clonogenic cells with the 
desired  genetic  modification.  Therefore,  this 
technique opens new and exciting possibilities. By 
modifying  the  ZFN binding  specificity  and 
selecting an appropriate donor sequence, one could 
target the IDLV-ZFN system to any individual site 
in the human genome avoiding random integration 
(Figure 1B) and, potentially, genome toxicity
88-91.
However,  there  are  current  obstacles  to 
successfully  apply  this  therapeutic  approach  to 
humans.  Some  of  them  include  the  need  for 
improved efficiency of gene delivery, insertion of 
the gene into non-oncogenic sites and the potential 
negative  or  positive  contributions  of  the  ß-
thalassemic genotype and potential modifiers to the 
effectiveness of the gene transfer
1. Original studies 
in animal models utilized mice with deletions of the 
ß-globin genes. These mutations do not reflect the 
phenotypic  variability  observed  in  ß-thalassemic 
patients. Thus, there is a gap in knowledge between 
our  understanding  of  the  primary  mutation,  the 
corresponding phenotype, and the approach to cure 
an individual patient based on his/her genotype (i.e.
understanding of  the  disease and its  treatment  by 
genetic modalities). To date this variability has not 
been addressed and no studies have focused on the 
efficacy of gene therapy in relation to the different 
genotypes of the patients. Although gene therapy is 
an  area  of  active  clinical  investigation,  the 
aforementioned  obstacles  limit  its  use  in  the 
management  of  thalassemia.  Nonetheless,  as  we 
showed  in  our  review  the  successful  transfer  of 
globin genes into hematopoietic cells of humans has 
been demonstrated and is encouraging.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure1. Schematic representation of the gene therapy approach mediated, respectively, by  (A) gene transfer into hematopoietic 
stem cells (HSC) using integration competent lentiviral vector (B) gene transfer into HSC by integrase defective lentiviral v
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oligonucleotides  and  triplex-forming  peptide 
nucleic acids (PNAs) have been shown to stimulate 
recombination in mammalian cells via site
binding  and  creation  of  altered  helical  structures 
that  provoke  DNA  repair
92,93.  Cotransfection  of 
PNAs  and  recombinatory  donor  DNA  fragments, 
Chin  and  co-workers  demonstrated  that  these 
complexes  can  promote  single  base
modification at the start of the second intron of the 
beta-globin gene, the site of a common thalassemia
associated mutation
94. This single base pair change 
was detected by the restoration of proper splicing of 
transcripts  produced  from  a  green  fluorescent 
protein-beta-globin fusion gene. The ability of these 
PNAs to  induce recombination  was dependent  on 
dose, sequence, cell-cycle stage, and the presence of 
a  homologous  donor  DNA  molecule.  They  also 
showed  that  these  PNAs  were  effective  in 
stimulating  the  modification  of  t
beta-globin locus in human cells, including primary 
hematopoietic  progenitor  cells.  Enhanced 
recombination, however, did not exhibit frequencies 
superior to 0.4%
94. However, this technology could 
be  a  powerful  tool  in  combination  with  th
generation of stem cells. In particular, introduction 
of the genes Oct3/4, Sox2 with either Klf4 and c
Myc  or  Nanog  and  Lin28  genes  can  induced 
pluripotent  stem  (iPS)  cells
95,115
coworkers  shown  that  iPS cells  can  be  generated 
from cells derived from skin fibroblasts, amniotic 
fluid or chorionic villus sampling of patients with ß
thalassemia
97.  Subsequently,  the  iPS  cells  were 
differentiated  into  hematopoietic  cells  that 
synthesized  hemoglobin.  Therefore,  in  the  future 
the mutation in the ß-globin gene of these iPS cells 
could be corrected by gene targeting and the cells 
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a  homologous  donor  DNA  molecule.  They  also 
showed  that  these  PNAs  were  effective  in 
stimulating  the  modification  of  the  endogenous 
globin locus in human cells, including primary 
hematopoietic  progenitor  cells.  Enhanced 
recombination, however, did not exhibit frequencies 
. However, this technology could 
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generation of stem cells. In particular, introduction 
of the genes Oct3/4, Sox2 with either Klf4 and c-
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cells  can  be  generated 
from cells derived from skin fibroblasts, amniotic 
fluid or chorionic villus sampling of patients with ß-
.  Subsequently,  the  iPS  cells  were 
matopoietic  cells  that 
synthesized  hemoglobin.  Therefore,  in  the  future 
globin gene of these iPS cells 
could be corrected by gene targeting and the cells 
differentiated  into  HSCs  to  be  returned  to  the 
patient
94. Figure 1C depicts this approach. In fact, 
mice  affected  by  SCD  were  cured  using  this 
strategy
98. However, there are som
need  to  be  overcome  before  iPS  treatment  of  ß
thalassemia  will  be  utilized.  One  of  the  most 
pressing problems is elimination of the transcription 
factors when they are no longer needed. Second, it 
is  necessary  to  reestablish  the  correct  re
programming so that the iPS cells do not develop 
into tumors. 
Splice-Switching and Stop Codon Readthrough
Defective  ß-globin  gene  expression  and  ß
deficiency  can  be  attributed  to  almost  200 
thalassemic mutations. However, only 10 mutations 
are responsible for the majority of cases worldwide 
and  some  of  the  most  frequent  cause  aberrant 
splicing of intron 1 (IVS1-110, IVS1
intron  2  (IVS2-654,  IVS2
mutations lead to incorrectly spliced mRNAs
though  the correct splice sites  remain undamaged 
and  potentially  functional.  Use  of  small  nuclear 
RNA  (snRNA)  and  splice
nucleotides represents a promising approach since 
these molecules can restore the corrected splicing 
re-establishing  the  synthesis  of  the  normal 
protein
94,100-108.  Therefore  blocking  the  aberrant 
splice  sites  with  antisense  oligonucleotides
the  splicing  machinery  to  reselect  the  existing 
correct splice  sites.  Expre
sequences targeted  to  the  aberrant  splice  sites  in 
thalassemic  pre-mRNA
restoring the correct splicing pattern and ultimately 
restoring  hemoglobin  synthesis
demonstrated in  HSCs  and  erythroid  progenitor 
cells  from a  patient  with  IVS2
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differentiated  into  HSCs  to  be  returned  to  the 
depicts this approach. In fact, 
mice  affected  by  SCD  were  cured  using  this 
. However, there are some obstacles that 
need  to  be  overcome  before  iPS  treatment  of  ß-
thalassemia  will  be  utilized.  One  of  the  most 
pressing problems is elimination of the transcription 
factors when they are no longer needed. Second, it 
is  necessary  to  reestablish  the  correct  re-
programming so that the iPS cells do not develop 
nd Stop Codon Readthrough:
globin  gene  expression  and  ß-globin 
deficiency  can  be  attributed  to  almost  200 
mutations. However, only 10 mutations 
are responsible for the majority of cases worldwide 
and  some  of  the  most  frequent  cause  aberrant 
110, IVS1-6, IVS1-5) or 
654,  IVS2-745)
99,112.  These 
mutations lead to incorrectly spliced mRNAs, even 
though  the correct splice sites  remain undamaged 
and  potentially  functional.  Use  of  small  nuclear 
RNA  (snRNA)  and  splice-switching  oligo-
nucleotides represents a promising approach since 
these molecules can restore the corrected splicing 
hing  the  synthesis  of  the  normal 
.  Therefore  blocking  the  aberrant 
splice  sites  with  antisense  oligonucleotides forces 
the  splicing  machinery  to  reselect  the  existing 
splice  sites.  Expression  of  antisense 
targeted  to  the  aberrant  splice  sites  in 
has  been  successful, 
restoring the correct splicing pattern and ultimately 
restoring  hemoglobin  synthesis
102,93.  This  was 
in  HSCs  and  erythroid  progenitor 
a  patient  with  IVS2-745/IVS2-1 Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
thalassemia. After transduction of the patient cells 
with  a  lentiviral  vector  that  express  a  snRNA 
targeting the  mutant  RNA, the  levels of  correctly 
spliced ß-globin mRNA and adult hemoglobin were 
approximately  25-fold  over  baseline
108.  Similarly, 
the correct splicing pattern was restored in a mouse 
model of IVS2-654 thalassemia. This was achieved 
by  delivery  in  vivo of  a  splice-switching 
oligonucleotide, a morpholino oligomer conjugated 
with  an  arginine-rich  peptide.  Repaired  ß-globin 
mRNA restored significant amounts of hemoglobin 
in  the  peripheral  blood  of  the  IVS2-654  mouse, 
improving  the  number  and  quality  of  erythroid 
cells
107. 
Another approach showing a great potential for 
the treatment of genetic disorders characterized by 
to premature termination codons (PTCs) is the use 
of drugs to induce stop codon readthrough. These 
modified RNA would protected against non-sense 
mediated  mRNA  decay  (NMD)  and  allow 
production  of  a  protein
109.  Aminoglycoside 
antibiotics can decrease the accuracy in the codon-
anticodon base pairing, inducing a ribosomal read 
through  of  premature  termination  codon.  These 
findings  have  led  to  the  development  of  a 
pharmacologic  approach  to  treat  thalassemic 
patients  carrying  the  ß0-39  mutation,  which 
introduces a PTC in codon 39 of the ß-globin gene 
and  is  one  of  the  most  frequent  thalassemic 
mutations  in  the  Mediterranean  littoral
1. 
Aminoglycosides  and  analogous  molecules  were 
tested  in  their  ability  to  restore  ß-globin  protein 
synthesis on human erythroid cells (K562) carrying 
a lentiviral construct containing the ß0-39 globin-
gene
110.  Treatment  of  these  cells  with  geneticin 
(G418)  and  other  aminoglycosides  restored  the 
production  of  ß-globin
110.  Moreover,  after  FACS 
and  high  performance  liquid  chromatography 
(HPLC) analyses, G418 was also demonstrated to 
partially correct the biological function of the ß0-39 
globin mRNA in erythroid precursor cells from ß0-
39 homozygous thalassemia patients
111. This study 
strongly  suggests  that  ribosomal  read-through 
should be considered a novel approach for treatment 
of ß0 thalassemia caused by premature stop codon 
mutations and NMD. 
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